THERAPIX BIOSCI/S (NASDAQ:TRPX) and Ritter Pharmaceuticals (NASDAQ:RTTR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.
Volatility and Risk
THERAPIX BIOSCI/S has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500. Comparatively, Ritter Pharmaceuticals has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500.
This table compares THERAPIX BIOSCI/S and Ritter Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares THERAPIX BIOSCI/S and Ritter Pharmaceuticals’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|THERAPIX BIOSCI/S||N/A||N/A||-$8.52 million||N/A||N/A|
|Ritter Pharmaceuticals||N/A||N/A||-$16.87 million||($3.66)||-0.23|
Institutional and Insider Ownership
3.1% of THERAPIX BIOSCI/S shares are held by institutional investors. Comparatively, 6.3% of Ritter Pharmaceuticals shares are held by institutional investors. 15.4% of Ritter Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This is a breakdown of recent recommendations for THERAPIX BIOSCI/S and Ritter Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Ritter Pharmaceuticals has a consensus price target of $15.00, indicating a potential upside of 1,686.35%. Given Ritter Pharmaceuticals’ higher probable upside, analysts plainly believe Ritter Pharmaceuticals is more favorable than THERAPIX BIOSCI/S.
About THERAPIX BIOSCI/S
Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include THX-110 for the treatment of Tourette syndrome, Obstructive Sleep Apnea, and pain; THX-130 for the treatment of Mild Cognitive Impairment and Traumatic Brain Injury; THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain. Therapix Biosciences Ltd. has a product development agreement with Cure Pharmaceutical to develop cannabinoid-based product for sleep disorders. The company was formerly known as NasVax Ltd. and changed its name to Therapix Biosciences Ltd. in November 2013. Therapix Biosciences Ltd. was founded in 2004 and is headquartered in Givatayim, Israel.
About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc. develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California.
Receive News & Ratings for THERAPIX BIOSCI/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for THERAPIX BIOSCI/S and related companies with MarketBeat.com's FREE daily email newsletter.